Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Services Institute of Medical Sciences, Pakistan
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients aged 18-70 years.
Both male or female.
End-stage kidney disease as per operational definition.
On a stable dialysis prescription for at least 3 months, with thrice-weekly sessions (or unit-standard schedule) and stable dry weight assessment.
Clinically stable over the preceding 4 weeks, with no hospitalization or acute intercurrent illness.
You may not be if
Cardiovascular instability: recurrent intradialytic hypotension (≥30% of sessions in the prior month requiring saline or early termination), uncontrolled hypertension (SBP \>180 mmHg or DBP \>110 mmHg despite therapy), recent acute coronary syndrome, stroke, or decompensated heart failure within 3 months.
Advanced hepatic disease (decompensated cirrhosis or refractory ascites), active systemic infection, chronic inflammatory disease flare, or active malignancy under treatment likely to confound fluid status or survival.
Recent blood transfusion within the preceding 4 weeks, or active bleeding, as these may distort hemoglobin and inflammatory indices.
Advanced chronic liver disease, nephrotic-range protein loss, or other conditions likely to substantially alter serum albumin independent of dialysis modality.
Parathyroidectomy history or current use of intravenous calcimimetics initiation/change within the preceding 4 weeks, if expected to markedly alter intact parathyroid hormone.
Adherence concerns: documented inability to follow fluid/salt advice or to attend scheduled treatments during the screening period; anticipated surgery or hospitalization within the study window.
Clareo Health | Comparing Hemodiafiltration to Conventional Hemodialysis: Effects on Clinical and Biochemical Parameters
